The Costs and Consequences of Methicillin‐Resistant <i>Staphylococcus aureus</i> Infection Treatments in Canada

Abstract

The estimated cost savings associated with linezolid use not only offset the higher acquisition cost of the anti-infective, but may be substantial to health care systems across Canada, especially as the incidence of MRSA continues to rise.